Related Experiment Video
Updated: Mar 25, 2026

Use of the Soft-agar Overlay Technique to Screen for Bacterially Produced Inhibitory Compounds
Published on: January 14, 2017
Identification and functional insights into new phage tail-like bacteriocins targeting Pseudomonas aeruginosa as new
Clara Ibarguren-Quiles1,2, Lucía Blasco1,2, Carla López-Causape2,3
1Multidisciplinary and Translational Microbiology group (MicroTM), Biomedical Research Institute of A Coruña (INIBIC), Microbiology Service, University Hospital of A Coruña (CHUAC), University of A Coruña (UDC), A Coruña, Spain.
Abstract:
The current health crisis caused by multidrug-resistant (MDR) pathogens is one of the health problems of most concern globally. Infections caused by these pathogens, such as Pseudomonas aeruginosa, lead to high rates of complications, particularly in compromised patients such as cystic fibrosis (CF) patients. The need to counteract and minimize the forecast future impact has led to the rescue of phage therapy. The use of bacteriophages has important advantages, including highly specific targeting, self-amplification at the infection site, minimal disruption of the microbiome, safety, and biocompatibility. However, the capacity of bacteria to escape these entities results in a form of resistance that compromises the effectiveness of the therapy. This involves the search for potential alternatives, such as the phage tail-like bacteriocins (PTLBs), also named as tailocins. These high-molecular-weight particles resemble the tail structure of bacteriophages and are characterized by the absence of genetic material, avoiding the development of resistance, one of the major handicaps associated with phage therapy. In this study, we detected 34 different PTLBs in 75 P. aeruginosa genomes, with different serotypes and sequence types, 11 of which were characterized as novel F-type PTLB subtypes (F13-F24). Furthermore, we report that four selected PTLBs (R1, F15, F19, and R3-F24) can deal with bacterial infection, with the R1 and the F15 PTLBs being the most efficient in clearing infection in vitro, yielding a survival rate of more than 75% in the Galleria mellonella larvae in vivo model. This reaffirms the potential of PTLBs to control P. aeruginosa infections, which can cause chronic infections in some patients, such as people with CF, due to its strong impact as a MDR bacterium.IMPORTANCEThe 75 Pseudomonas aeruginosa genomes from people with cystic fibrosis in the study collection included at least one phage tail-like bacteriocins (PTLB) cluster. From the 34 different PTLBs detected in the study collection, 7 were R-type, 10 were complex (R- and F-type encoded), and 14 were F-type PTLBs. Eleven new F-type PTLBs were described in the P. aeruginosa collection under study. An association between the O-antigen present on the surface of the P. aeruginosa isolate and the encoded PTLB subtype was detected. The R1 and F15 PTLB subtypes display high antimicrobial activity both in vitro and in vivo (Galleria mellonella).
Insights
Phage tail-like bacteriocins (PTLBs) show promise against multidrug-resistant Pseudomonas aeruginosa infections, offering an alternative to phage therapy. Specific PTLB subtypes, R1 and F15, demonstrated significant efficacy in clearing infections both in vitro and in vivo.
Area of Science:
- Microbiology and Infectious Diseases
- Bacteriophage Research
- Antimicrobial Resistance
Background:
- Multidrug-resistant (MDR) pathogens, like Pseudomonas aeruginosa, pose a significant global health threat, especially to immunocompromised individuals such as cystic fibrosis (CF) patients.
- Phage therapy is a promising alternative, but bacterial resistance can limit its effectiveness.
- Phage tail-like bacteriocins (PTLBs) are emerging as a potential solution due to their specific targeting and lack of genetic material, which prevents resistance development.
Purpose of the Study:
- To investigate the potential of PTLBs as an alternative therapeutic strategy against MDR Pseudomonas aeruginosa.
- To identify and characterize novel PTLB subtypes within P. aeruginosa genomes.
- To evaluate the efficacy of selected PTLBs against P. aeruginosa infections in vitro and in vivo.
Main Methods:
- Bioinformatic analysis of 75 Pseudomonas aeruginosa genomes to detect and classify PTLB clusters.
- Characterization of novel F-type PTLB subtypes.
- In vitro antimicrobial activity assays and in vivo Galleria mellonella infection models to assess the efficacy of selected PTLBs (R1, F15, F19, R3-F24).
Main Results:
- Thirty-four different PTLBs were identified in 75 P. aeruginosa genomes, including 11 novel F-type PTLB subtypes (F13-F24).
- An association was found between P. aeruginosa O-antigen serotypes and encoded PTLB subtypes.
- The R1 and F15 PTLB subtypes exhibited the highest antimicrobial activity, achieving over 75% survival in Galleria mellonella larvae models.
Conclusions:
- PTLBs represent a viable alternative for combating multidrug-resistant Pseudomonas aeruginosa infections, particularly in vulnerable populations like CF patients.
- The identified novel PTLB subtypes and the demonstrated efficacy of R1 and F15 PTLBs highlight their therapeutic potential.
- PTLBs offer a promising strategy to overcome the limitations of traditional phage therapy by circumventing bacterial resistance mechanisms.
Related Concept Videos
Gene Regulation in Microbial Communities: Quorum Sensing
Lytic Cycle of Bacteriophages
DNA Bacteriophages
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Clinical Significance of Antibiotic Resistance
CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...

